Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
March 06, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE...
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
February 22, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
February 07, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Issues Letter to Shareholders
January 09, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
December 04, 2023 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
November 20, 2023 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 09:00 ET
|
Atossa Therapeutics, Inc.
Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023...
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
November 09, 2023 09:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
September 18, 2023 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 08:30 ET
|
Atossa Therapeutics, Inc.
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver...